These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension. Iannone F, Riccardi MT, Guiducci S, Bizzoca R, Cinelli M, Matucci-Cerinic M, Lapadula G. Ann Rheum Dis; 2008 Aug; 67(8):1121-6. PubMed ID: 18029384 [Abstract] [Full Text] [Related]
4. The endothelin receptor antagonist bosentan improves peripheral endothelial function in patients with type 2 diabetes mellitus and microalbuminuria: a randomised trial. Rafnsson A, Böhm F, Settergren M, Gonon A, Brismar K, Pernow J. Diabetologia; 2012 Mar; 55(3):600-7. PubMed ID: 22200728 [Abstract] [Full Text] [Related]
9. Assessment of vascular function in systemic sclerosis: indications of the development of nitrate tolerance as a result of enhanced endothelial nitric oxide production. Andersen GN, Mincheva-Nilsson L, Kazzam E, Nyberg G, Klintland N, Petersson AS, Rantapää-Dahlqvist S, Waldenström A, Caidahl K. Arthritis Rheum; 2002 May; 46(5):1324-32. PubMed ID: 12115240 [Abstract] [Full Text] [Related]
12. The endothelin-1 receptor antagonist bosentan protects against ischaemia/reperfusion-induced endothelial dysfunction in humans. Böhm F, Settergren M, Gonon AT, Pernow J. Clin Sci (Lond); 2005 Apr; 108(4):357-63. PubMed ID: 15610070 [Abstract] [Full Text] [Related]
13. No changes in N-terminal pro-brain natriuretic peptide in a longitudinal cohort of patients with systemic sclerosis-associated pulmonary arterial hypertension on therapy with bosentan. Rotondo C, Praino E, Nivuori M, di Serio F, Lapadula G, Iannone F. Int J Rheum Dis; 2017 Jan; 20(1):90-96. PubMed ID: 26218502 [Abstract] [Full Text] [Related]
18. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Launay D, Sitbon O, Le Pavec J, Savale L, Tchérakian C, Yaïci A, Achouh L, Parent F, Jais X, Simonneau G, Humbert M. Rheumatology (Oxford); 2010 Mar; 49(3):490-500. PubMed ID: 20015974 [Abstract] [Full Text] [Related]